drugset
drugset / Trial / NCT06174779

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

NCT06174779 ↗

Phase 3 Completed 448 enrolled Hanmi Pharmaceutical Company Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

Timeline

Start
2024-01-03
Primary completion
2025-08-14
Completion
2026-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Efpeglenatide Peptide — Subcutaneous

Indications

obesity disorder